Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 47, Issue 8, Pages 2442-2444Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.47.8.2442-2444.2003
Keywords
-
Categories
Funding
- NIAID NIH HHS [U19-AI40974] Funding Source: Medline
Ask authors/readers for more resources
The use of gatifloxacin (GAT) in combination with ethionamide (ETA) with or without pyrazinamide (PZA) for a 12-week treatment period followed by an 8-week observation period was evaluated in a model of tuberculosis in mice. Mice treated with GAT at 300 mg/kg of body weight in combination with ETA (25 mg/kg) for 5 days per week had sterile lungs, whereas mice treated with GAT (100 mg/kg) and ETA (25 mg/kg) had about 10 CFU/lung; however, there was regrowth of the organisms in both groups at the end of the observation period. When PZA (450 mg/kg 5 days per week) was added to the high-dose GAT-ETA regimen, no viable mycobacteria were present after the 8-week observation period. GAT in combination with ETA and PZA has great promise for the treatment of tuberculosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available